| Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. | |
| | |
MedLine Citation:
|
PMID: 9759984 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The present study aimed to investigate the influence of the angiotensin-converting enzyme (ACE)-inhibitor captopril and the Ca-antagonist nifedipine on endothelium-dependent vasodilation (EDV) in the forearm of hypertensive patients. Twenty-three middle-aged untreated hypertensive patients underwent evaluation of EDV and endothelium-independent vasodilation (EIDV) in the forearm, by means of local intra-arterial infusions of methacholine (MCh, evaluating EDV) and sodium-nitroprusside (SNP, evaluating EIDV), before and 1 h after intake of either captopril (25 mg) or nifedipine (10 mg) in a randomised, double-blind fashion. A matched normotensive control group was investigated at baseline conditions only. Five of the hypertensives were also evaluated after 3 months of treatment with captopril 25 mg twice daily in an open pilot study. First, the vasodilation induced by methacholine (MCh), but not SNP, was significantly attenuated in the hypertensive patients compared to the normotensive controls (P < 0.001 at MCh 4 microg/min). Second, although the two drugs induced a similar decline in blood pressure (BP) 1 h after administration (-11 to 10 mm Hg/-8 to 7 mm Hg), captopril significantly potentiated the vasodilator response to MCh (+32+/-13%, MCh 4 micr og/min, P < 0.01) but not SNP, while nifedipine did not significantly alter the response to either MCh or SNP. The improvement in vasodilator response to MCh induced by captopril was closely related to the reduction in BP (r = 0.72, P < 0.01). Third, in the pilot study, 3 months of captopril treatment induced a significant potentiation of the vasodilator response to MCh (+34+/-17%, MCh 4 microg/min, P < 0.05) in parallel with a significant BP reduction (-22+/-24/13+/-13 mm Hg, P < 0.05), while the response to SNP was unchanged. In conclusion, the present study confirmed that essential hypertension is associated with a defect in EDV. Furthermore, an improvement in EDV was seen in hypertensive patients shortly after administration of captopril, but not nifedipine. In addition, a significant beneficial effect on EDV was seen in a small pilot study during long-term treatment with captopril. |
| | |
Authors:
|
J Millgård; A Hägg; M Sarabi; L Lind |
Related Documents
:
|
10333164 - Undesirable blood pressure changes under naturalistic treatment with moclobemide, a rev... 12420044 - Human coagulation factor xii-related "new pressor protein": role of pacap in its cardio... 7594444 - Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hype... 11904534 - Tissue angiotensin-converting enzyme activity plays an important role in pressure overl... 26734 - Effect on the cushing response of different rates of expansion of a supratentorial mass. 12747274 - Systemic sclerosis is not associated with clinical or ambulatory blood pressure. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of human hypertension Volume: 12 ISSN: 0950-9240 ISO Abbreviation: J Hum Hypertens Publication Date: 1998 Aug |
Date Detail:
|
Created Date: 1998-11-24 Completed Date: 1998-11-24 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8811625 Medline TA: J Hum Hypertens Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 511-6 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, University Hospital of Uppsala, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiotensin-Converting Enzyme Inhibitors / pharmacology*, therapeutic use Arteries / physiopathology Calcium Channel Blockers / pharmacology, therapeutic use Captopril / pharmacology*, therapeutic use Double-Blind Method Endothelium, Vascular / drug effects, physiopathology Female Forearm / blood supply Humans Hypertension / drug therapy*, physiopathology* Male Middle Aged Nifedipine / pharmacology*, therapeutic use Vasodilation / drug effects* Vasodilator Agents / pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Calcium Channel Blockers; 0/Vasodilator Agents; 21829-25-4/Nifedipine; 62571-86-2/Captopril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of losartan on hypertension and left ventricular mass: a long-term study.
Next Document: Vascular and neuroendocrine components in altered blood pressure regulation after surgical repair of...